Find Aficamten manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Aficamten [inn], Aficamten [usan], 2364554-48-1, B1i77mh6k1, Chembl4847050, Ck-3773274
Molecular Formula
C18H19N5O2
Molecular Weight
337.4  g/mol
InChI Key
IOVAZWDIRCRMTM-OAHLLOKOSA-N
FDA UNII
B1I77MH6K1

Aficamten
1 2D Structure

Aficamten

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[(1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl]-1-methylpyrazole-4-carboxamide
2.1.2 InChI
InChI=1S/C18H19N5O2/c1-3-16-21-17(22-25-16)12-4-6-14-11(8-12)5-7-15(14)20-18(24)13-9-19-23(2)10-13/h4,6,8-10,15H,3,5,7H2,1-2H3,(H,20,24)/t15-/m1/s1
2.1.3 InChI Key
IOVAZWDIRCRMTM-OAHLLOKOSA-N
2.1.4 Canonical SMILES
CCC1=NC(=NO1)C2=CC3=C(C=C2)C(CC3)NC(=O)C4=CN(N=C4)C
2.1.5 Isomeric SMILES
CCC1=NC(=NO1)C2=CC3=C(C=C2)[C@@H](CC3)NC(=O)C4=CN(N=C4)C
2.2 Other Identifiers
2.2.1 UNII
B1I77MH6K1
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Aficamten [inn]

2. Aficamten [usan]

3. 2364554-48-1

4. B1i77mh6k1

5. Chembl4847050

6. Ck-3773274

7. 1h-pyrazole-4-carboxamide, N-((1r)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-

8. N-((1r)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)- 1-methyl-1h-pyrazole-4-carboxamide

9. Unii-b1i77mh6k1

10. Schembl21179170

11. Gtpl11524

12. Ex-a5344

13. Bdbm50575173

14. Ck-274

15. Who 11544

16. Ck3773274

17. Hy-139465

18. Ck-3773274;ck-274

19. Cs-0202223

20. (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide

21. N-[(1r)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl]-1-methylpyrazole-4-carboxamide

2.4 Create Date
2019-11-02
3 Chemical and Physical Properties
Molecular Weight 337.4 g/mol
Molecular Formula C18H19N5O2
XLogP32.1
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count4
Exact Mass337.15387487 g/mol
Monoisotopic Mass337.15387487 g/mol
Topological Polar Surface Area85.8 Ų
Heavy Atom Count25
Formal Charge0
Complexity490
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

NDC API

read-more
read-more

01

CPHI Middle east
Not Confirmed
arrow
arrow
CPHI Middle east
Not Confirmed

AFICAMTEN

NDC Package Code : 59116-6280

Start Marketing Date : 2020-04-06

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty